Onconova stock: buy or sell?
December 6th, 2019
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer.
Should I buy Onconova stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Onconova stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Onconova Therapeutics stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we gathered 4 ratings published for ONTX stock in the last 30 days. The general sentiment of these ratings is bullish for ONTX stock, with 4 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
Onconova stock analysis
After sliding a dreadful -10.34% yesterday, Onconova Therapeutics closed today at $0.35 and climbed an outstanding 20.69%.
After sliding a dreadful -10.34% yesterday, Onconova Therapeutics closed today at $0.35 and climbed an outstanding 20.69%. Since last September when ONTX stock price broke down the SMA50d line, it slid $-2.15 per share (-86.00%).
By mid November ONTX plunged a spooky -133.33% in just one week. Onconova skyrocketed an extraordinary 84.21% this week.
Since late June, when ONTX stock price broke down the 20-weeks moving avarage line, it slid $-3.40 per share (-90.67%).
Onconova stock price history
Onconova IPO was on July 25th, 2013 at $3,750.00 per share1. Since then, ONTX stock lost a -100.00%, with a yearly average of -16.70%.
1: Adjusted price after possible price splits or reverse-splits.
Onconova stock historical price chart
ONTX stock reached 52-week highs on March at $4.83, and all-time highs 2013-10-04 with a price of 4669.5.
Onconova stock price target is $19.50Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we found 4 price forecasts for ONTX stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-3-26||HC Wainwright||Set Price Target||n/a||$25.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOnconova disappointed analysts on March when it posted an Earnings per Share (EPS) of $-0.85 when the market consensus was $-1.09.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Onconova Therapeutics annual revenues boosted a dazzling 56.04% to $1.23 M USD from $0.79 marked in 2017. When comparing 2018 vs 2017, in the same way, profit margin (that is, the net income divided by revenues) rocketed a 1,385.92% to -1,675.33%.
|2013||$4.75 M||-||$-64.86 M-1365.5%||-|
|2014||$0.80 M||-83.16%||$-63.68 M-7960.2%||-1.82%|
|2015||$11 M||1,332.00%||$-23.98 M-209.3%||-62.35%|
|2016||$5.55 M||-51.59%||$-19.67 M-354.6%||-17.98%|
|2017||$0.79 M||-85.81%||$-24.09 M-3061.2%||22.50%|
|2018||$1.23 M||56.04%||$-20.57 M-1675.3%||-14.61%|
Quarterly financial resultsOnconova Therapeutics posted $0.06 M in sales for 2018-Q4, a -50.83% decline compared to previous quarter. Reported quarter income marked $-5.65 M with a profit margin of -9,577.97%. Profit margin plunged a -5,121.30% compared to previous quarter when profit margin was -4,456.67%. When comparing sales to same quarter last year, Onconova sales marked a frightening correction and plummed a -58.74%. Looking back to recent quarterly results, Onconova posted 3 negative quarters in a row.
|2017-Q1||$0.21 M||-||$-8.34 M-3971.4%||-|
|2017-Q2||$0.32 M||54.29%||$-2.58 M-796.3%||-69.06%|
|2017-Q3||$0.11 M||-66.05%||$-6.96 M-6328.2%||169.81%|
|2017-Q4||$0.14 M||30.00%||$-6.21 M-4340.6%||-10.83%|
|2018-Q1||$0.56 M||294.41%||$-5.09 M-902.5%||-18.00%|
|2018-Q2||$0.49 M||-14.01%||$-4.48 M-924.5%||-11.91%|
|2018-Q3||$0.12 M||-75.26%||$-5.35 M-4456.7%||19.27%|
|2018-Q4||$0.06 M||-50.83%||$-5.65 M-9578.0%||5.67%|
Onconova ownershipWhen you are planning to buy a company, it's worth to check its ownership structure.
Onconova shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 4.76% of all shares.
In case of Onconova stock, 59.20% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ONTX stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Onconova Therapeutics:
|Market cap||$13.5 M|
|Total shares||38.5 M|
|Float shares||5.7 M|
|- Institutional holdings (%)||59.2%|
|- Insider holdings (%)||4.8%|
|Shares in short selling||0.0%|
|Friday, December 6th, 2019|
|Day range||$0.34 - $0.38|
|Average true range||$0.10|
|50d mov avg||$0.57|
|100d mov avg||$1.41|
|200d mov avg||$2.49|
Onconova performanceTo measure stock performance is always good to compare with competitors or related stocks. For Onconova Therapeutics, the benchmark is made against .